MA. ANTONIA
SALUD SALVIA
TEU
![Foto de MA. ANTONIA](/img/nophoto.png)
![Foto de Instituto Valenciano de Oncologia](/img/noimage_org.png)
Instituto Valenciano de Oncologia
Valencia, EspañaPublicaciones en colaboración con investigadores/as de Instituto Valenciano de Oncologia (8)
2020
-
Breakthrough cancer pain: review and calls to action to improve its management
Clinical and Translational Oncology, Vol. 22, Núm. 8, pp. 1216-1226
2019
-
Clinical impact of circulating tumor RAS and BRAF mutation dynamics in patients with metastatic colorectal cancer treated with first-line chemotherapy plus anti–epidermal growth factor receptor therapy
JCO Precision Oncology, Vol. 3
-
Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy before Standard Chemoradiotherapy and Surgery in Patients with High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical Trial
JAMA Oncology, Vol. 5, Núm. 11, pp. 1566-1573
2018
-
Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients
Neoplasia (United States), Vol. 20, Núm. 7, pp. 678-686
2017
-
MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: Long-term results from the GEMCAD 0801 trial
Annals of Oncology, Vol. 28, Núm. 2, pp. 344-353
-
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer
British Journal of Cancer, Vol. 117, Núm. 12, pp. 1777-1786
2014
2010
-
Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo Cáncer de Recto 3 study
Journal of Clinical Oncology, Vol. 28, Núm. 5, pp. 859-865